Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Role of the complement system in ischaemic heart disease - Potential for pharmacological intervention
Autore:
Shernan, SK; Collard, CD;
Indirizzi:
Texas Heart Inst, Div Cardiovasc Anesthesiol, Houston, TX 77225 USA Texas Heart Inst Houston TX USA 77225 Anesthesiol, Houston, TX 77225 USA Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA Harvard Univ Boston MA USA 02115 ioperat & Pain Med, Boston, MA 02115 USA
Titolo Testata:
BIODRUGS
fascicolo: 9, volume: 15, anno: 2001,
pagine: 595 - 607
SICI:
1173-8804(2001)15:9<595:ROTCSI>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
MEMBRANE ATTACK COMPLEX; TUMOR-NECROSIS-FACTOR; ISCHEMIA-REPERFUSION INJURY; C1 ESTERASE INHIBITOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY OCCLUSION; C5A RECEPTOR ANTAGONISTS; CARDIOPULMONARY BYPASS; ENDOTHELIAL-CELLS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
133
Recensione:
Indirizzi per estratti:
Indirizzo: Collard, CD Texas Heart Inst, Div Cardiovasc Anesthesiol, MCI-226,POB 20345, Houston, TX 77225 USA Texas Heart Inst MCI-226,POB 20345 Houston TX USA 77225 25 USA
Citazione:
S.K. Shernan e C.D. Collard, "Role of the complement system in ischaemic heart disease - Potential for pharmacological intervention", BIODRUGS, 15(9), 2001, pp. 595-607

Abstract

The complement system is an innate. cytotoxic host defence system that normally functions to eliminate foreign pathogens. However, considerable evidence suggests that complement plays a key role in the pathophysiology of ischaemic heart disease (IHD). Experimental models of acute myocardial infarction (MI) and autopsy specimens taken from acute MI patients demonstrate that complement is selectively deposited in areas of infarction. Furthermore, inhibition of complement activation or depletion of complement components prior to myocardial reperfusion has been shown to reduce complement-mediatedtissue injury in numerous animal models. IHD remains a leading cause of patient morbidity and mortality. Considerable effort in recent years has therefore been directed by biotechnology and pharmaceutical industries towards the development of novel, human complement inhibitors. Proposed anticomplement therapeutic strategies include the administration of naturally occurring or recombinant complement regulators, anticomplement monoclonal antibodies, and anticomplement receptor antagonists. Although data regarding the effectiveness of anticomplement therapy in humans is limited at present, a number of novel anticomplement therapeutic strategies are currently in clinical trials. The role of complement in IHD and potential for pharmacological intervention is reviewed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 15:54:12